Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 2/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.42 |
| ▸ | MGAM | O43451 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 4/20 | 0.41 |
| ▸ | SI | P14410 | 4/20 | 0.41 |
| ▸ | MGAM2 | Q2M2H8 | 4/20 | 0.41 |
| ▸ | GUSB | P08236 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9213937 | 0.82 | NR3C1 (0.51) | NR3C1NR3C2MGAMGAASI | |
| SCHEMBL16433322 | 0.80 | SLC6A4 (0.55) | SLC6A4 | |
| SCHEMBL15556005 | 0.80 | SLC6A4 (0.54) | SLC6A4 | |
| SCHEMBL5239895 | 0.75 | HTR2A (0.48) | MGAMGAASIMGAM2GUSB | |
| SCHEMBL15544356 | 0.72 | MAPT (0.63) | NR3C1NR3C2MEN1KMT2AKDM4E | |
| SCHEMBL16824131 | 0.71 | HTR6 (0.41) | NR3C1NR3C2MEN1KMT2ASLC6A4 | |
| SCHEMBL20078269 | 0.70 | GUSB (0.50) | MGAMGAASIMGAM2GUSB | |
| SCHEMBL16824124 | 0.69 | SLC6A4 (0.41) | NR3C1NR3C2MEN1KMT2AKDM4E | |
| SCHEMBL24842242 | 0.69 | DRD2 (0.41) | NR3C1NR3C2KMT2APGRBCHE | |
| SCHEMBL10754767 | 0.68 | GAA (0.42) | NR3C1NR3C2MGAMGAASI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10316025-B2 | Substituted piperazine compounds and methods of use and use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2019-06-11 | — | — | US | disclosed |
| US-20180179188-A1 | SUBSTITUTED PIPERAZINE COMPOUNDS AND METHODS OF USE AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179188-A1 | SUBSTITUTED PIPERAZINE COMPOUNDS AND METHODS OF USE AND USE THEREOF | HTR5A, HTR2C, TPH1 | NR3C1 752/4885NR3C2 401/4885MGAM 4581/4885 |
| US-10316025-B2 | Substituted piperazine compounds and methods of use and use thereof | HTR5A, HTR2C, TPH1 | NR3C1 752/4885NR3C2 401/4885MGAM 4581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.